2010-04-14
Added · Updated
The Financial Crimes Enforcement Network amends 31 CFR Part 103 to include mutual funds within the general definition of financial institution, subjecting them to Currency Transaction Report requirements and the Recordkeeping and Travel Rule for fund transmittals. Mutual funds must file Currency Transaction Reports for currency transfers exceeding $10,000 and retain records for fund transmittals equal to or exceeding $3,000, with a compliance deadline of January 10, 2011. The rule also harmonizes the definition of mutual fund in the anti-money laundering program rule and clarifies that examination authority for Bank Secrecy Act compliance is delegated to the Securities and Exchange Commission rather than the Internal Revenue Service.
FINCEN published 7 documents in the last 30 days — get each new one by email the day it lands.
1Language expanding the scope of the BSA was added by the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (‘‘USA PATRIOT Act’’), Public Law 107–56. 2 31 U.S.C. 5312(a)(2)(I). 3See 15 U.S.C. 80a–3. 4 15 U.S.C. 80a–4; 15 U.S.C. 80a–5(a)(1); 15 U.S.C. 80a–2(a)(32). Face-amount certificate companies and unit investment trusts are excluded from the definition of ‘‘management company.’’ 15 U.S.C. 80a–4(3). 5Anti-Money Laundering Programs for Mutual Funds, 67 FR 21117 (April 29, 2002); Customer Identification Programs for Mutual Funds, 68 FR 25131 (May 9, 2003); Amendment to the Bank Secrecy Act Regulations—Requirement That Mutual Funds Report Suspicious Activity, 71 FR 26213 (May 4, 2006); Anti-Money Laundering Programs; Special Due Diligence Programs for Certain Foreign Accounts, 71 FR 496 (Jan. 4, 2006); Anti-Money Continued Epidemiology & Statistics Unit, Research and Scientific Affairs, January 2009.
10. Mannino, D. M. et al., ‘‘Surveillance for
Asthma—United States, 1980–1999,’’ Morbidity and Mortality Weekly Report, 51(SS01):1–13, March 29, 2002.
11. Analysis completed by FDA based on
information provided by IMS Health, IMS National Sales Perspective (TM), 2009, extracted September 2009. These data can be purchased from IMS Health. Please send all inquiries to: IMS Health, Attn: Brian Palumbo, Account Manager, 660 West Germantown Pike, Plymouth Meeting, PA 19462.
12. Rozek, R. P., and E. R. Bishko,
‘‘Economic Issues Raised in the FDA’s Proposed Rule on Removing the EssentialUse Designation for Albuterol MDIs,’’ National Economic Research Associates, August 13, 2004 (FDA Docket No. 2003P– 0029/C25).
13. Hendeles, L. G, L. Colice, and R. J.
Meyer, ‘‘Withdrawal of Albuterol Inhalers Containing Chlorofluorocarbon Propellants,’’ New England Journal of Medicine, 356:1344– 1351, March 29, 2007.
14. Goldman, D. P. et al., ‘‘Pharmacy
Benefits and the Use of Drugs by the Chronically Ill,’’ The Journal of the American Medical Association, 291:2344–2350, May 19, 2004.
15. DeNavas-Walt, C., B. D. Proctor, and J.
C. Smith, U.S. Census Bureau, Current
Population Reports, P60–236(RV), Income, Poverty, and Health Insurance Coverage in the United States: 2008, Table 7, p. 21, 2009. List of Subjects in 21 CFR Part 2 Administrative practice and procedure, Cosmetics, Drugs, Foods.
Read the rest free, and get an email when FINCEN publishes again
Source: Financial Crimes Enforcement Network — original document · Summary generated with machine assistance and reviewed before publication; the authoritative text is the regulator's original document. How RegAlert works
More like this from FINCEN
FINCEN published 7 documents in the last 30 days. We email you each new one the day it's published.